How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Healthcare and Pharmaceuticals · Forecast 2027–2033
Tomography Test Phantom Market
- By Modality: CT Phantom, MRI Phantom, PET Phantom, Ultrasound Phantom, SPECT Phantom
- By Application: Quality Assurance Phantom, Calibration Phantom, Training Phantom, Research Phantom, Dosimetry Phantom
- By Material: Acrylic, Polyurethane, Silicone, Gel-based, Water-equivalent
- By Phantom Design: Anthropomorphic Phantom, Geometric Phantom, Slice Phantom, Multi-modality Phantom
- By End User: Hospitals, Diagnostic Imaging Centers, Research Institutes, Phantom Manufacturers, Academic Institutions
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - CT Phantom leads By Modality at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 10 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
12 chapters · 291 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.66 →
- 11 Competitive Landscape 5 sections p.184 →
- 12 Company Profiles 10 players: SWOT & benchmarking p.192 →
Full report · locked preview
Everything inside the Tomography Test Phantom Market report
A complete, evidence-based study - 12 chapters and 122 sections covering market size, segmentation across 5 axes, regional analysis and 10 company profiles, forecast to 2033.
Segmentation covered
Modality 5
Application 5
Material 5
Phantom Design 4
End User 5
Companies profiled
CIRS (Computerized Imaging Reference Systems)
The Phantom Laboratory
QRM GmbH
Modus Medical Devices Inc.
Standard Imaging Inc.
Leeds Test Objects Ltd.
Gammex (a Sun Nuclear company)
Nuclear Associates (a subsidiary of Fluke Biomedical)
IBA Dosimetry
PTW-Freiburg GmbH
Verified · Analyst-reviewed · No payment to preview
Trusted & certified by
★★★★★ Excellent
★★★★★ Excellent
10 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →CIRS (Computerized Imaging Reference Systems)
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →The Phantom Laboratory
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →QRM GmbH
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →Modus Medical Devices Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →Standard Imaging Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.178 →Leeds Test Objects Ltd.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.184 →Gammex (a Sun Nuclear company)
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.191 →Nuclear Associates (a subsidiary of Fluke Biomedical)
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →IBA Dosimetry
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.202 →PTW-Freiburg GmbH
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.209 →Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Global · 2025–2033
$6,800M by 2033 · 7.9% CAGR
Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- CT Phantom50.8
- MRI Phantom9.7
- PET Phantom9.2
- Ultrasound Phantom15.4
- SPECT Phantom14.9
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →North America$1,219M → $2,165M · 7.4%
Europe$849.4M → $1,672M · 8.8%
Asia Pacific$775.6M → $1,464M · 8.3%
Latin America$480.1M → $991.6M · 9.5%
Middle East and Africa$369.3M → $612.7M · 6.5%
Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →7.872026
7.902027
7.902028
7.922029
7.922030
7.952031
7.962032
7.972033
CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- CIRS (Computerized Imaging Reference Systems)20.3
- The Phantom Laboratory16.3
- QRM GmbH9.0
- Modus Medical Devices Inc.9.8
- Standard Imaging Inc.9.5
- Leeds Test Objects Ltd.7.1
- Others28.0
Segment contribution to growth (%)
Fig. 18 · p.39 →Modality25.2%
Application17.6%
Material15.6%
Phantom Design12.9%
End User28.7%
Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America31.4
- Europe24.2
- Asia Pacific21.2
- Latin America14.4
- Middle East and Africa8.9
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| CIRS (Computerized Imaging Reference Systems) | 82 | 74 | 90 | 92 | 88 | 78 | 84 |
| The Phantom Laboratory | 93 | 84 | 93 | 90 | 80 | 71 | 85 |
| QRM GmbH | 87 | 77 | 68 | 65 | 74 | 66 | 73 |
| Modus Medical Devices Inc. | 80 | 61 | 63 | 59 | 75 | 67 | 68 |
| Standard Imaging Inc. | 58 | 64 | 57 | 77 | 68 | 70 | 66 |
| Leeds Test Objects Ltd. | 48 | 65 | 64 | 71 | 63 | 55 | 61 |
| Gammex (a Sun Nuclear company) | 41 | 59 | 65 | 46 | 41 | 47 | 50 |
| Nuclear Associates (a subsidiary of Fluke Biomedical) | 35 | 53 | 48 | 39 | 41 | 58 | 46 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- CIRS (Computerized Imaging Reference Systems)
- The Phantom Laboratory
- QRM GmbH
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| CIRS (Computerized Imaging Reference Systems) | ◐ | ◐ | ◐ | ✓ | ✓ | ✓ |
| The Phantom Laboratory | ✓ | ✓ | ◐ | ◐ | ◐ | ◐ |
| QRM GmbH | ✓ | ✓ | ◐ | − | ✓ | − |
| Modus Medical Devices Inc. | ✓ | ◐ | − | ◐ | ◐ | ✓ |
| Standard Imaging Inc. | ◐ | ✓ | ◐ | ◐ | ✓ | ◐ |
| Leeds Test Objects Ltd. | − | ◐ | ◐ | ◐ | − | ◐ |
| Gammex (a Sun Nuclear company) | ◐ | ◐ | ◐ | − | − | − |
| Nuclear Associates (a subsidiary of Fluke Biomedical) | − | − | ◐ | − | − | − |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →1The Phantom Laboratory85
2CIRS (Computerized Imaging Reference Systems)84
3QRM GmbH73
4Modus Medical Devices Inc.68
5Standard Imaging Inc.66
6Leeds Test Objects Ltd.61
7Gammex (a Sun Nuclear company)50
8Nuclear Associates (a subsidiary of Fluke Biomedical)46
Competitive tiers
§8.4 · p.172 →Leader2
Set the pace on share, breadth and innovation.
CIRS (Computerized Imaging Reference Systems)The Phantom Laboratory
Challenger2
Strong scale, closing on the leaders.
QRM GmbHModus Medical Devices Inc.
Contender2
Focused players with pockets of strength.
Standard Imaging Inc.Leeds Test Objects Ltd.
Niche2
Specialists in a single segment or region.
Gammex (a Sun Nuclear company)Nuclear Associates (a subsidiary of Fluke Biomedical)
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Go-to-market strategy
Land Modality in North America, then scale across Tomography Test Phantom Market — a $494M beachhead inside a $7.68B market.
Beachhead (SOM)$494Mobtainable near-term
Serviceable (SAM)$3.06Breachable market
Primary motionDirect + partner-ledgo-to-market
Time to scale4 Qto full motion
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Champion92 fit
CT Phantom
Best fit — highest urgency & budget in Modality.
Economic buyer78 fit
MRI Phantom
Strong fit — clear ROI and a fast path to value.
End user65 fit
PET Phantom
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Modality in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add Application & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + Material
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Direct sales44%
Partner / channel26%
Digital / self-serve22%
Marketplaces8%
Positioning & messaging
§GTM 2 · p.194 →For Modality leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win Tomography Test Phantom Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Awareness100%
Marketing qualified42%
Sales qualified25%
Evaluation12%
Closed-won6%
$16.1KCAC
$95KLTV
5.9:1LTV : CAC
< 4 moCAC payback
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Investment thesis
Tomography Test Phantom Market is a durable-growth opportunity — $3.01B by 2033, compounding at 8.9%.
TAM · 2025$1.52Btoday
TAM · 2033$3.01Bforecast
CAGR8.9%2027–2033
Cumulative$19.7Brevenue opportunity
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →TAM$3.01BTotal addressable market
SAM$1.26BServiceable available market
SOM$258MServiceable obtainable market
Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →8.9% CAGR
Demand compounds through 2033, outpacing GDP across Modality.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Modality moving from early to mainstream — durable secular demand.
Consolidation upside
10+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →$3.01BLarge & growingTAM by 2033 at 8.9% CAGR
$1.26BServiceable nowreachable with today’s model
$258MBeachhead winobtainable near-term share
10+Fragmented fieldplayers — consolidation runway
Return scenarios (2033 market value)
Fig. 6 · p.22 →$2.35BBear5.8% CAGR
$3.01BBase8.9% CAGR
$3.86BBull11.8% CAGR
Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & Application optionality
- Customer concentrationBroaden installed base beyond top accounts
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Board pack · executive summary
Tomography Test Phantom Market — a $6.55B market by 2033. Plan: grow share from 5.2% to 11.2%.
Market size · 2033$6.55Btotal addressable
Market CAGR8.5%2027–2033
Target share11.2%from 5.2% today
Revenue ambition$734Mby 2033
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 5.2% | 11.2% | At risk |
| Revenue | $336M | $734M | Behind |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | At risk |
| Segment coverage | 3 of 5 axes | 5 of 5 axes | On track |
| Gross margin | 29.8% | 43.1% | On track |
| Customer retention | 91.0% | 95.2% | At risk |
Where to play (strategic priorities)
§1.2 · p.8 →1
Lead segment
Win in Modality
Largest revenue pool and fastest secular demand — concentrate to build share here first.
2
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
3
Adjacency
Build Application capability
A defensible second engine — invest in Application to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Modality share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch Application
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $86M capacity & capability investment
- Greenlight bolt-on M&A in Application
- Authorise North America expansion plan
- Fund R&D program for Modality leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownBehind
- Competitive share lossBehind
- Input-cost & supply riskBehind
- Regulatory / policy changeOn track
- Execution & talentOn track
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Sales deck · value proposition
Win the Tomography Test Phantom Market conversation — a $3.98B market you can size, segment and defend in minutes.
Market size · 2033$3.98Btotal opportunity
Growth4.5%CAGR to 2033
Addressable buyers1,604+accounts in scope
Typical ROI5.3×in year one
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Modality
Goal Grow share in Modality
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →Decisions made on stale, generic dataLive, source-cited figures, continuously updated
Weeks waiting on a research vendorA full report compiled in minutes
No view of competitors or whitespaceCompany profiles, ACE matrix & benchmarking
Hard to defend the numbers internallyEvery figure traceable to its original source
The business case (ROI)
Fig. 2 · p.9 →5.3×return on cost, year one
< 2 mopayback period
$65K+research cost avoided
10×faster than a custom study
Time to insight
Cost to run
Risk of a wrong call
Why buyers trust it (proof points)
§1.3 · p.12 →600K+source studies indexed
100%analyst-reviewed
10+players profiled in this market
Coverage includes
CIRS (Computerized Imaging Reference Systems)The Phantom LaboratoryQRM GmbHModus Medical Devices Inc.Standard Imaging Inc.Leeds Test Objects Ltd.Gammex (a Sun Nuclear company)Nuclear Associates (a subsidiary of Fluke Biomedical)+2 more
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Most popular
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your Tomography Test Phantom Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
or continue with your email
Your report is ready to access
Tomography Test Phantom Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Healthcare and Pharmaceuticals · scroll →Tomato Soft Capsules Market
Market size, share, segmentation and regional forecast.
$448M market · 2025 base year
View reportTolvaptan Market
Market size, share, segmentation and regional forecast.
$366M market · 2025 base year
View reportTolvaptan API Market
Market size, share, segmentation and regional forecast.
$2.4B market · 2025 base year
View reportToltrazuril API Market
Market size, share, segmentation and regional forecast.
$2.0B market · 2025 base year
View reportTolterodine Tartrate Market
Market size, share, segmentation and regional forecast.
$3.3B market · 2025 base year
View reportTolterodine Tartrate API Market
Market size, share, segmentation and regional forecast.
$1.6B market · 2025 base year
View reportTolterodine Tartarate Market
Market size, share, segmentation and regional forecast.
$3.7B market · 2025 base year
View reportTolnaftate Market
Market size, share, segmentation and regional forecast.
$4.6B market · 2025 base year
View reportTolcapone Market
Market size, share, segmentation and regional forecast.
$2.9B market · 2025 base year
View reportTolbutamide Market
Market size, share, segmentation and regional forecast.
$3.6B market · 2025 base year
View reportToilet Support & Surrounds Market
Market size, share, segmentation and regional forecast.
$5.8B market · 2025 base year
View reportToilet Safety Rail Market
Market size, share, segmentation and regional forecast.
$3.2B market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
WinnerVMR Custom Report
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
Off-the-shelf PDF
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
600,000+source studies indexed
100%analyst-reviewed
Every figuresource-cited & traceable
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy
Questions, answered
How is the research actually conducted?
Every report is compiled from VMR’s continuously-updated intelligence across 600,000+ source studies - primary interviews, company filings, trade data, and government & industry databases. Figures are triangulated across multiple credible sources, then reviewed by a research analyst before your report is delivered.
What exactly do I get inside the report?
A full multi-chapter study: market definition & methodology, executive summary, market outlook (drivers, restraints, trends, Porter’s Five Forces), segment deep-dives, regional & country breakdowns, competitive landscape, and a full profile for every company you select - with interactive charts and data tables throughout.
How accurate are the numbers, and can I trust them?
Market sizing is reconciled across leading sources (Gartner, BCG, MarketsandMarkets, government bodies and more), with outliers removed and a confidence-graded median used for the base year. Every figure is source-cited and traceable to its origin, and an analyst validates the model before delivery.
Can I customise the chapters, regions and companies?
Yes. Choose exactly the chapters, regions and countries, and the companies you want benchmarked before you build - then adjust your selection and recompile anytime from your account. You only pay for the scope you need.
What formats do I receive, and is the data editable?
Every report is readable online in full. Downloadable formats are available as optional $99 add-ons: a formatted PDF and a fully editable XLSX containing all underlying data tables - so you can re-chart, re-model, or drop any figure straight into your own deck.